Aptinyx Sees Path Forward In DPN With Long-Term Patients

18 Apr 2019

After disappointing top-line Phase II data in diabetic peripheral neuropathy with NYX-2925, Aptinyx says the full dataset shows significance across endpoints in patients four years or more past diagnosis; a second Phase II study in this subgroup is planned.

Neuropathy that is the damage of peripheral nerves that causes pain and loss of sensation in the extremities. — Neuropathy is damage of peripheral nerves that causes pain and loss of sensation in the extremities

Aptinyx Inc. said “stay tuned” after missing the primary and secondary endpoints in a Phase II study of its NMDA modulator NYX-2925 in diabetic peripheral neuropathy (DPN) in January. Now, the Chicago-area firm has released a subgroup analysis showing that DPN patients who have had the disease four years or longer look like optimal subjects for a subsequent Phase II study.

Aptinyx announced on April 18 that a review of the completed Phase II study was presented at the American Pain...